Expression of DNMTs and genomic DNA methylation in gastric signet ring cell carcinoma

Molecular Medicine Reports

Volumn 8, Issue 3, 2013, Pages 942-948

  He, Miao ^a   Fan, Jing ^a   Jiang, Rong ^b   Tang, Wei Xue ^a   Wang, Zi Wei ^a  

^a THE FIRST AFFILIATED HOSPITAL OF CHONGQING MEDICAL UNIVERSITY   (China)

^b CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

DNA methylation; DNA methyltransferases; Epigenetics; Gastric cancer; Signet ring cell carcinoma

Indexed keywords

ABELSON KINASE; DNA METHYLTRANSFERASE; DNA METHYLTRANSFERASE 1; DNA METHYLTRANSFERASE 3B; FIBROBLAST GROWTH FACTOR 18; GENOMIC DNA; PROTEIN ABL2; PROTEIN EGFL7; PROTEIN RAB33A; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 2; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CPG ISLAND; DNA DETERMINATION; DNA METHYLATION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; MALE; MICROARRAY ANALYSIS; PROTEIN DETERMINATION; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SIGNET RING CARCINOMA; STOMACH CARCINOMA;

AGED; CARCINOMA, SIGNET RING CELL; CPG ISLANDS; DNA (CYTOSINE-5-)-METHYLTRANSFERASE; DNA METHYLATION; DNA MODIFICATION METHYLASES; FEMALE; HUMANS; IMMUNOPRECIPITATION; MALE; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROMOTER REGIONS, GENETIC; REAL-TIME POLYMERASE CHAIN REACTION; STOMACH NEOPLASMS;

EID: 84881159161     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2013.1566     Document Type: Article

References (57)

1. Esteller M: Cancer Epigenetics for the 21st Century: What's Next? Genes Cancer 2: 604-606, 2011.
2. Daniel FI, Cherubini K, Yurgel LS, de Figueiredo MA and Salum FG: The role of epigenetic transcription repression and DNA methyltransferases in cancer. Cancer 117: 677-687, 2011.
3. Bender CM, Pao MM and Jones PA: Inhibition of DNA methylation by 5-aza-2'-deoxycytidine suppresses the growth of human tumor cell lines. Cancer Res 58: 95-101, 1998.
4. Fang JY, Cheng ZH, Chen YX, Lu R, Yang L, Zhu HY and Lu LG: Expression of Dnmt1, demethylase, MeCP2 and methylation of tumor-related genes in human gastric cancer. World J Gastroenterol 10: 3394-3398, 2004.
5. Choi MS, Shim YH, Hwa JY, Lee SK, Ro JY, Kim JS and Yu E: Expression of DNA methyltransferases in multistep hepatocarcinogenesis. Hum Pathol 34: 11-17, 2003.
6. Ding WJ, Fang JY, Chen XY and Peng YS: The expression and clinical significance of DNA methyltransferase proteins in human gastric cancer. Dig Dis Sci 53: 2083-2089, 2008.
7. Peng DF, Kanai Y, Sawada M, Ushijima S, Hiraoka N, Kosuge T and Hirohashi S: Increased DNA methyltransferase 1 (DNMT1) protein expression in precancerous conditions and ductal carcinomas of the pancreas. Cancer Sci 96: 403-408, 2005.
8. Arai E, Kanai Y, Ushijima S, Fujimoto H, Mukai K and Hirohashi S: Regional DNA hypermethylation and DNA methyltransferase (DNMT) 1 protein overexpression in both renal tumors and corresponding nontumorous renal tissues. Int J Cancer 119: 288-296, 2006.
9. Vertino PM, Yen RW, Gao J and Baylin SB: De novo methylation of CpG island sequences in human fibroblasts overexpressing DNA (cytosine-5-)- methyltransferase. Mol Cell Biol 16: 4555-4565, 1996.
10. Klotz DM, Nelson SA, Kroboth K, Newton IP, Radulescu S, Ridgway RA, Sansom OJ, Appleton PL and Näthke IS: The microtubule poison vinorelbine kills cells independently of mitotic arrest and targets cells lacking the APC tumour suppressor more effectively. J Cell Sci 125: 887-895, 2012.
11. Ohta S, Lai EW, Pang AL, Brouwers FM, Chan WY, Eisenhofer G, de Krijger R, Ksinantova L, Breza J, Blazicek P, Kvetnansky R, Wesley RA and Pacak K: Downregulation of metastasis suppressor genes in malignant pheochromocytoma. Int J Cancer 114: 139-143, 2005.
12. Gilham DE, Debets R, Pule M, Hawkins RE and Abken H: CAR-T cells and solid tumors: tuning T cells to challenge an inveterate foe. Trends Mol Med 18: 377-384, 2012.
13. Riccio A and Cubellis MV: Gain of function in CDKN1C. Nat Genet 44: 737-738, 2012.
14. Harinck F, Kluijt I, van der Stoep N, Oldenburg RA, Wagner A, Aalfs CM, Sijmons RH, Poley JW, Kuipers EJ, Fockens P, van Os TA and Bruno MJ: Indication for CDKN2A-mutation analysis in familial pancreatic cancer families without melanomas. J Med Genet 49: 362-365, 2012.
15. Guan CN, Zhang PW, Lou HQ, Liao XH and Chen BY: DLC-1 expression levels in breast cancer assessed by qRT-PCR are negatively associated with malignancy. Asian Pac J Cancer Prev 13: 1231-1233, 2012.
16. Liu J, Lin Y, Yang H, Deng Q, Chen G and He J: The expression of p33(ING1), p53 and autophagy-related gene Beclin1 in patients with non-small cell lung cancer. Tumour Biol 32: 1113-1121, 2011.
17. Schultz DC, Vanderveer L, Berman DB, Hamilton TC, Wong AJ and Godwin AK: Identification of two candidate tumor suppressor genes on chromosome 17p13.3. Cancer Res 56: 1997-2002, 1996.
18. Vaidyanathan G, Cismowski MJ, Wang G, Vincent TS, Brown KD and Lanier SM: The Ras-related protein AGS1/RASD1 suppresses cell growth. Oncogene 23: 5858-5863, 2004.
19. Berman SD, Calo E, Landman AS, Danielian PS, Miller ES, West JC, Fonhoue BD, Caron A, Bronson R, Bouxsein ML, Mukherjee S and Lees JA: Metastatic osteosarcoma induced by inactivation of Rb and p53 in the osteoblast lineage. Proc Natl Acad Sci USA 105: 11851-11856, 2008.
20. Kanwal S, Kayani MA and Faryal R: Identification of novel SNPs in SYK gene of breast cancer patients: computational analysis of SNPs in the 5'UTR. Mol Biol Rep 39: 8345-8351, 2012.
21. Behjati R, Kawai K, Inadome Y, Kano J, Akaza H and Noguchi M: APAF-1 is related to an undifferentiated state in the testicular germ cell tumor pathway. Cancer Sci 102: 267-274, 2011.
22. Chêne L, Giroud C, Desgrandchamps F, Boccon-Gibod L, Cussenot O, Berthon P and Latil A: Extensive analysis of the 7q31 region in human prostate tumors supports TES as the best candidate tumor suppressor gene. Int J Cancer 111: 798-804, 2004.
23. da Costa Prando E, Cavalli LR and Rainho CA: Evidence of epigenetic regulation of the tumor suppressor gene cluster flanking RASSF1 in breast cancer cell lines. Epigenetics 6: 1413-1424, 2011.
24. Takahashi M, Fujita M, Furukawa Y, Hamamoto R, Shimokawa T, Miwa N, Ogawa M and Nakamura Y: Isolation of a novel human gene, APCDD1, as a direct target of the beta-Catenin/T-cell factor 4 complex with probable involvement in colorectal carcinogenesis. Cancer Res 62: 5651-5656, 2002.
25. Agueli C, Cammarata G, Salemi D, Dagnino L, Nicoletti R, La Rosa M, Messana F, Marfia A, Bica MG, Coniglio ML, Pagano M, Fabbiano F and Santoro A: 14q32/miRNA clusters loss of heterozygosity in acute lymphoblastic leukemia is associated with up-regulation of BCL11a. Am J Hematol 85: 575-578, 2010.
26. Zhang X, Liu H, Li B, Huang P, Shao J and He Z: Tumor suppressor BLU inhibits proliferation of nasopharyngeal carcinoma cells by regulation of cell cycle, c-Jun N-terminal kinase and the cyclin D1 promoter. BMC Cancer 12: 267, 2012.
27. Wheeler SE, Morariu EM, Bednash JS, Otte CG, Seethala RR, Chiosea SI and Grandis JR: Lyn kinase mediates cell motility and tumor growth in EGFRvIII-expressing head and neck cancer. Clin Cancer Res 18: 2850-2860, 2012.
28. Persson M andrén Y, Moskaluk CA, Frierson HF Jr, Cooke SL, Futreal PA, Kling T, Nelander S, Nordkvist A, Persson F and Stenman G: Clinically significant copy number alterations and complex rearrangements of MYB and NFIB in head and neck adenoid cystic carcinoma. Genes Chromosomes Cancer 51: 805-817, 2012.
29. Xiong F, Wu C, Chang J, Yu D, Xu B, Yuan P, Zhai K, Xu J, Tan W and Lin D: Genetic variation in an miRNA-1827 binding site in MYCL1 alters susceptibility to small-cell lung cancer. Cancer Res 71: 5175-5181, 2011.
30. Gilmore TD and Gerondakis S: The c-Rel transcription factor in development and disease. Genes Cancer 2: 695-711, 2011.
31. Zhang L, Teng Y, Zhang Y, Liu J, Xu L, Qu J, Hou K, Yang X, Liu Y and Qu X: C-Src-mediated RANKL-induced breast cancer cell migration by activation of the ERK and Akt pathway. Oncol Lett 3: 395-400, 2012.
32. Memarian A, Hojjat-Farsangi M, Asgarian-Omran H, Younesi V, Jeddi-Tehrani M, Sharifian RA, Khoshnoodi J, Razavi SM, Rabbani H and Shokri F: Variation in WNT genes expression in different subtypes of chronic lymphocytic leukemia. Leuk Lymphoma 50: 2061-2070, 2009.
33. Dwyer MA, Joseph JD, Wade HE, Eaton ML, Kunder RS, Kazmin D, Chang CY and McDonnell DP: WNT11 expression is induced by estrogen-related receptor alpha and beta-catenin and acts in an autocrine manner to increase cancer cell migration. Cancer Res 70: 9298-9308, 2010.
34. Tanic M, Yanowsky K, Rodriguez-Antona C, Andrés R, Márquez-Rodas I, Osorio A, Benitez J and Martinez-Delgado B: Deregulated miRNAs in hereditary breast cancer revealed a role for miR-30c in regulating KRAS oncogene. PLoS One 7: e38847, 2012.
35. Qiu JF, Zhang ZQ, Wang Y and You J: Lentivirus-mediated RNAi knockdown of VEGFA in RKO colorectal cancer cells decreases tumor formation and growth in vitro and in vivo. Int J Clin Exp Pathol 5: 290-298, 2012.
36. Seyhan AA, Varadarajan U, Choe S, Liu W and Ryan TE: A genome-wide RNAi screen identifies novel targets of neratinib resistance leading to identification of potential drug resistant genetic markers. Mol Biosyst 8: 1553-1570, 2012.
37. Shen DW and Gottesman MM: RAB8 enhances TMEM205-mediated cisplatin resistance. Pharm Res 29: 643-650, 2012.
38. Wang JS, Wang FB, Zhang QG, Shen ZZ and Shao ZM: Enhanced expression of Rab27A gene by breast cancer cells promoting invasiveness and the metastasis potential by secretion of insulin-like growth factor-II. Mol Cancer Res 6: 372-382, 2008.
39. Shibata D, Mori Y, Cai K, Zhang L, Yin J, Elahi A, Hamelin R, Wong YF, Lo WK, Chung TK, Sato F, Karpeh MS Jr and Meltzer SJ: RAB32 hypermethylation and microsatellite instability in gastric and endometrial adenocarcinomas. Int J Cancer 119: 801-806, 2006.
40. Cong XL, Li B, Yang RC, Feng SZ, Chen SJ and Han ZC: Enhanced growth suppression of Philadephia1 leukemia cells by targeting bcr3/abl2 and VEGF through antisense strategy. Leukemia 19: 1517-1524, 2005.
41. Sonvilla G, Allerstorfer S, Stättner S, Karner J, Klimpfinger M, Fischer H, Grasl-Kraupp B, Holzmann K, Berger W, Wrba F, Marian B and Grusch M: FGF18 in colorectal tumour cells: autocrine and paracrine effects. Carcinogenesis 29: 15-24, 2008.
42. Delfortrie S, Pinte S, Mattot V, Samson C, Villain G, Caetano B, Lauridant-Philippin G, Baranzelli MC, Bonneterre J, Trottein F, Faveeuw C and Soncin F: Egfl7 promotes tumor escape from immunity by repressing endothelial cell activation. Cancer Res 71: 7176-7186, 2011.
43. Schenone S, Brullo C, Musumeci F, Biava M, Falchi F and Botta M: Fyn kinase in brain diseases and cancer: the search for inhibitors. Curr Med Chem 18: 2921-2942, 2011.
44. Jacobs JF, van Bokhoven H, van Leeuwen FN, Hulsbergen-van de Kaa CA, de Vries IJ, Adema GJ, Hoogerbrugge PM and de Brouwer AP: Regulation of MYCN expression in human neuroblastoma cells. BMC Cancer 9: 239, 2009.
45. Lankat-Buttgereit B, Fehmann HC, Hering BJ, Bretzel RG and Göke B: Expression of the ras-related rab3a gene in human insulinomas and normal human pancreatic islets. Pancreas 9: 434-438, 1994.
46. Jang KW, Lee KH, Kim SH, Jin T, Choi EY, Jeon HJ, Kim E, Han YS and Chung JH: Ubiquitin ligase CHIP induces TRAF2 proteasomal degradation and NF-κB inactivation to regulate breast cancer cell invasion. J Cell Biochem 112: 3612-3620, 2011.
47. Kawaguchi-Ihara N, Murohashi I, Nara N and Tohda S: Promotion of the self-renewal capacity of human acute leukemia cells by Wnt3A. Anticancer Res 28: 2701-2704, 2008.
48. Charlton A, Blair V, Shaw D, Parry S, Guilford P and Martin IG: Hereditary diffuse gastric cancer: predominance of multiple foci of signet ring cell carcinoma in distal stomach and transitional zone. Gut 53: 814-820, 2004.
49. Rountree MR, Bachman KE, Herman JG and Baylin SB: DNA methylation, chromatin inheritance and cancer. Oncogene 20: 3156-3165, 2001.
50. Schaefer M, Hagemann S, Hanna K and Lyko F: Azacytidine inhibits RNA methylation at DNMT2 target sites in human cancer cell lines. Cancer Res 69: 8127-8132, 2009.
51. Ooi SK, Qiu C, Bernstein E, Li K, Jia D, Yang Z, Erdjument-Bromage H, Tempst P, Lin SP, Allis CD, Cheng X and Bestor TH: DNMT3L connects unmethylated lysine 4 of histone H3 to de novo methylation of DNA. Nature 448: 714-717, 2007.
52. Bourc'his D, Xu GL, Lin CS, Bollman B and Bestor TH: Dnmt3L and the establishment of maternal genomic imprints. Science 294: 2536-2539, 2001.
53. Jia D, Jurkowska RZ, Zhang X, Jeltsch A and Cheng X: Structure of Dnmt3a bound to Dnmt3L suggests a model for de novo DNA methylation. Nature 449: 248-251, 2007.
54. Stefanska B, Huang J, Bhattacharyya B, Suderman M, Hallett M, Han ZG and Szyf M: Definition of the landscape of promoter DNA hypomethylation in liver cancer. Cancer Res 71: 5891-5903, 2011.
55. Tan AC, Jimeno A, Lin SH, Wheelhouse J, Chan F, Solomon A, Rajeshkumar NV, Rubio-Viqueira B and Hidalgo M: Characterizing DNA methylation patterns in pancreatic cancer genome. Mol Oncol 3: 425-438, 2009.
56. Dimberg J, Ström K, Löfgren S, Zar N, Lindh M and Matussek A: DNA promoter methylation status and protein expression of interleukin-8 in human colorectal adenocarcinomas. Int J Colorectal Dis 27: 709-714, 2012.
57. Radhakrishnan VM, Jensen TJ, Cui H, Futscher BW and Martinez JD: Hypomethylation of the 14-3-3σ promoter leads to increased expression in non-small cell lung cancer. Genes Chromosomes Cancer 50: 830-836, 2011.